Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Enzymatic Blood Test Could Detect Prediabetes

By LabMedica International staff writers
Posted on 20 Jul 2010
A pilot study reports that O-linked beta-N-acetylglucosamine (O-GlcNAc), an easy-to-detect enzyme in erythrocytes is up to two to three times higher in people with diabetes and pre-diabetes than in those with no disease.

Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA) studied blood samples from volunteers with no diabetes (36 samples), prediabetes (13 samples), and diabetes (53 samples), according to traditional tests that require patient fasting. More...
Erythrocyte proteins were then extracted from the samples, and the hemoglobins were depleted. Then, global O-GlcNAcylation (O-GlcNAc) of the proteins was confirmed by Western blotting using an O-GlcNAc-specific antibody. Relative O-GlcNAc transferase (OGT) and O-GlcNAcase--an enzyme that removes O-GlcNAc in red blood cells--protein amounts were similarly determined. The relative expression of O-GlcNAcase was then compared with the measured level of A1C.

The results showed that erythrocyte proteins are highly O-GlcNAcylated, and O-GlcNAcase expression is significantly increased in erythrocytes from both individuals with prediabetes and diabetes, compared with normal control subjects. However, unlike O-GlcNAcase, protein levels of OGT did not show significant changes. The researchers therefore suggest that the upregulation of O-GlcNAcase might be an adaptive response to hyperglycemia-induced increases in O-GlcNAcylation, which are likely deleterious to erythrocyte functions. The study was published in the July 2010 issue of Diabetes.

"This is an example of how basic research is directly affecting a serious disease,” said Gerald Hart, Ph.D., director of biological chemistry at the JHU School of Medicine. "The question was whether the elevation happened in the earliest stages of diabetes and therefore might have value as a diagnostic tool. Only a much larger clinical trial will determine if, by measuring O-GlcNAcase, we can accurately diagnose prediabetes.”

O-GlcNAc plays an important role in the development of insulin resistance and glucose toxicity, since it modifies many of the cell's proteins to control their functions in response to nutrients (such as glucose and lipids) and stress. O-GlcNAcylation is regulated by OGT, which attaches O-GlcNAc to serine and/or threonine residues of proteins, and by O-GlcNAcase, which removes O-GlcNAc. When the extent of O-GlcNAc attached to proteins becomes too high, as occurs in diabetes, it is harmful to the cell.

Related Links:

Johns Hopkins University




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.